Literature DB >> 20416990

[Vasculitis assessment with [18F]FDG positron emission tomography].

E Liozon1, J Monteil, K H Ly, E Vidal.   

Abstract

[18F]fluorodeoxyglucose positron emission tomography (PET) is a noninvasive metabolic imaging modality that is well-suited to the assessment of activity and extent of large vessel vasculitis. PET imaging has demonstrated its usefulness in diagnosing giant cell arteritis (notably in its silent form), Takayasu's arteritis, and unclassified aortitis. PET imaging could be more effective than magnetic resonance imaging in detecting the earliest stages of vascular wall inflammation. The visual grading of vascular [18F]FDG uptake makes it possible to discriminate arteritis from active atherosclerosis, providing therefore high specificity. High sensitivity can also be achieved provided scanning is performed during active inflammatory phase, preferably before starting corticosteroid treatment. Prospective studies are needed to determine the exact value of PET imaging in assessing other vasculitis subsets, infectious aortitis, and large vessel vasculitis outcome and response to immunosuppressive treatment. Copyright 2010 Société nationale française de médecine interne (SNFMI). Published by Elsevier SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20416990     DOI: 10.1016/j.revmed.2009.06.011

Source DB:  PubMed          Journal:  Rev Med Interne        ISSN: 0248-8663            Impact factor:   0.728


  2 in total

1.  Magnetic resonance imaging in the diagnosis and follow-up of giant cell arteritis: case report and review of literature.

Authors:  Ana Gudelj Gračanin; Josip Ćurić; Jelena Lončarević; Jadranka Morović-Vergles
Journal:  Eur J Rheumatol       Date:  2015-04-22

2.  F-18 Fdg PET/CT Findings of a Patient with Takayasu Arteritis Before and After Therapy.

Authors:  Sait Sağer; Sabire Yılmaz; Meftune Ozhan; Metin Halaç; Nurhan Ergül; Hediye Ciftci; T Fikret Cermik
Journal:  Mol Imaging Radionucl Ther       Date:  2012-04-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.